ClinicalTrials.Veeva
Menu

Find clinical trials for Lymphoma in Berlin, BE

CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones

Related conditions:

B-Cell Lymphoma
Leukemia
Non-Hodgkin Lymphoma
Lymphoid Leukemia
Diffuse Large B-Cell Lymphoma
Precursor Cell Lymphoblastic Leukemia-Lymphoma
B-Cell Chronic Lymphocytic Leukemia

Lymphoma trials near Berlin, BE, DEU:

Tisagenlecleucel in Adult Patients With Aggressive B-cell Non-Hodgkin Lymphoma (BELINDA)

Of Care in adult patients with aggressive B-cell Non-Hodgkin Lymphoma after failure of rituximab and anthracycline containing frontline immu...

Active, not recruiting
Non-Hodgkin Lymphoma
Drug: Platinum-based immunochemotherapy followed in responding patients with high dose chemotherapy and autologous hematopoietic stem cell transplant (HSCT)
Drug: Tisagenlecleucel after optional bridging and lymphodepleting chemotherapy

Phase 3

Novartis
Novartis

Berlin, Germany and 66 other locations

with Refractory/Relapsing (R/R) KIR3DL2 positive Peripheral T Cell Lymphoma (PTCL) : Not Other Specified (NOS), PTCL-TFH (including Angioimm...

Enrolling
Peripheral T Cell Lymphoma
Relapse/Recurrence
Drug: Lacutamab
Drug: Gemcitabine

Phase 2

The Lymphoma Academic Research Organisation

Berlin, Germany and 63 other locations

The goal of this clinical trial is to study the addition of Acalabrutinib to standard R-miniCHOP in older adults with DLBCL. The main question it aim...

Enrolling
Large B-cell Lymphoma
Diffuse Large B Cell Lymphoma
Drug: R-miniCHOP + Acalabrutinib
Drug: R-miniCHOP

Phase 3

Universität des Saarlandes

Berlin, Germany and 16 other locations

and preliminary efficacy of relatlimab plus nivolumab in pediatric and young adult participants with recurrent or refractory classical Hodgkin lymphoma...

Enrolling
Lymphoma, Non-Hodgkin
Hodgkin Disease
Drug: Relatlimab
Drug: Nivolumab

Phase 1, Phase 2

Bristol-Myers Squibb (BMS)
Bristol-Myers Squibb (BMS)

Berlin, Germany and 73 other locations

Combined modality approach using Obitunuzumab and involved site low dose irradiation in early stage nodal follicular lymphoma. Radiation dos...

Active, not recruiting
Stage II Grade 2 Follicular Lymphoma
Stage I Follicular Lymphoma Grade 1
Drug: Obinutuzumab Injection [Gazyva]
Radiation: Low dose radiation Therapy (LDRT)

Phase 2

Heidelberg University

Berlin, Berlin, Germany and 11 other locations

or obinutuzumab) in subjects with relapsed or refractory (R/R) lymphoma. Subjects must have received at least 2 prior lines of therapy, and ...

Active, not recruiting
Lymphoma
Drug: CC-220
Drug: Rituximab

Phase 1

Celgene
Celgene

Berlin, Germany and 25 other locations

pharmacokinetics, pharmacodynamics, and anti-tumor activity of DR-01 in adult patients with large granular lymphocytic leukemia or cytotoxic lymphomas...

Enrolling
Other CD8+/NK Cell Driven Lymphoma Not Listed Above
Subcutaneous Panniculitis-Like T-Cell Lymphoma
Drug: DR-01

Phase 1, Phase 2

Dren Bio

Berlin, Germany and 31 other locations

The purpose of this trial is to measure the following in participants with relapsed and/or refractory B-cell lymphoma who receive epcoritama...

Active, not recruiting
Small Lymphocytic Lymphoma (SLL)
Marginal Zone Lymphoma (MZL)
Biological: Epcoritamab

Phase 1, Phase 2

Genmab
Genmab

Berlin, Germany and 84 other locations

The purpose of this study was to evaluate whether copanlisib in combination with rituximab is superior to placebo in combination with rituximab in pr...

Active, not recruiting
Lymphoma,Non-Hodgkin
Drug: Placebo
Drug: Copanlisib (Aliqopa, BAY80-6946)

Phase 3

Bayer
Bayer

Berlin, Germany and 186 other locations

This study evaluates the addition of nivolumab to gemcitabine, oxaliplatin plus rituximab in case of B-cell lymphoma...

Active, not recruiting
Lymphoma, Non-Hodgkin
Device: Oxaliplatin
Drug: Rituximab

Phase 2, Phase 3

Universität des Saarlandes

Berlin, Germany and 76 other locations

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems